Literature DB >> 20052711

Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases.

Douglas J Marcotte1, Yu-Ting Liu, Robert M Arduini, Catherine A Hession, Konrad Miatkowski, Craig P Wildes, Patrick F Cullen, Victor Hong, Brian T Hopkins, Elisabeth Mertsching, Tracy J Jenkins, Michael J Romanowski, Darren P Baker, Laura F Silvian.   

Abstract

Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation. Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resolution, ligand-bound BTK structure. Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 A resolution or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin- 7-yl-cyclopentane at 1.6 A resolution. This data provides information relevant to the development of small molecule inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases. Analysis of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20052711      PMCID: PMC2866269          DOI: 10.1002/pro.321

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  29 in total

1.  Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck I.

Authors:  L D Arnold; D J Calderwood; R W Dixon; D N Johnston; J S Kamens; R Munschauer; P Rafferty; S E Ratnofsky
Journal:  Bioorg Med Chem Lett       Date:  2000-10-02       Impact factor: 2.823

2.  Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc.

Authors:  Matthäus Getlik; Christian Grütter; Jeffrey R Simard; Sabine Klüter; Matthias Rabiller; Haridas B Rode; Armin Robubi; Daniel Rauh
Journal:  J Med Chem       Date:  2009-07-09       Impact factor: 7.446

3.  Transphosphorylation of Bruton's tyrosine kinase on tyrosine 551 is critical for B cell antigen receptor function.

Authors:  T Kurosaki; M Kurosaki
Journal:  J Biol Chem       Date:  1997-06-20       Impact factor: 5.157

Review 4.  X-linked agammaglobulinemia and Bruton's tyrosine kinase.

Authors:  S Tsukada; O N Witte
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

5.  The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.

Authors:  Sandra W Cowan-Jacob; Gabriele Fendrich; Paul W Manley; Wolfgang Jahnke; Doriano Fabbro; Janis Liebetanz; Thomas Meyer
Journal:  Structure       Date:  2005-06       Impact factor: 5.006

6.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

7.  Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).

Authors:  Fatih M Uckun; Ilker Dibirdik; Sanjive Qazi; Alexei Vassilev; Hong Ma; Chen Mao; Alexey Benyumov; Katayoon H Emami
Journal:  Bioorg Med Chem       Date:  2006-10-26       Impact factor: 3.641

8.  The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases.

Authors:  D Vetrie; I Vorechovský; P Sideras; J Holland; A Davies; F Flinter; L Hammarström; C Kinnon; R Levinsky; M Bobrow
Journal:  Nature       Date:  1993-01-21       Impact factor: 49.962

9.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases.

Authors:  Todd A Carter; Lisa M Wodicka; Neil P Shah; Anne Marie Velasco; Miles A Fabian; Daniel K Treiber; Zdravko V Milanov; Corey E Atteridge; William H Biggs; Philip T Edeen; Mark Floyd; Julia M Ford; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Shamal A Mehta; Hitesh K Patel; William Pao; Charles L Sawyers; Harold Varmus; Patrick P Zarrinkar; David J Lockhart
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-26       Impact factor: 11.205

10.  The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.

Authors:  Oliver Hantschel; Uwe Rix; Uwe Schmidt; Tilmann Bürckstümmer; Michael Kneidinger; Gregor Schütze; Jacques Colinge; Keiryn L Bennett; Wilfried Ellmeier; Peter Valent; Giulio Superti-Furga
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-07       Impact factor: 11.205

View more
  46 in total

Review 1.  T-cell signaling regulated by the Tec family kinase, Itk.

Authors:  Amy H Andreotti; Pamela L Schwartzberg; Raji E Joseph; Leslie J Berg
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-02       Impact factor: 10.005

Review 2.  Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Authors:  Caspar da Cunha-Bang; Carsten Utoft Niemann
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

3.  Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.

Authors:  Andreas Kuglstatter; April Wong; Stan Tsing; Simon W Lee; Yan Lou; Armando G Villaseñor; J Michael Bradshaw; David Shaw; Jim W Barnett; Michelle F Browner
Journal:  Protein Sci       Date:  2011-02       Impact factor: 6.725

4.  Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.

Authors:  Aditya Sharma; B K Thelma
Journal:  J Mol Model       Date:  2019-06-06       Impact factor: 1.810

5.  Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.

Authors:  Shenqiu Wang; Sayan Mondal; Chunying Zhao; Marjan Berishaj; Phani Ghanakota; Connie Lee Batlevi; Ahmet Dogan; Venkatraman E Seshan; Robert Abel; Michael R Green; Anas Younes; Hans-Guido Wendel
Journal:  JCI Insight       Date:  2019-06-20

6.  Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.

Authors:  Brahmam Pujala; Anil K Agarwal; Sandip Middya; Monali Banerjee; Arjun Surya; Anjan K Nayak; Ashu Gupta; Sweta Khare; Rambabu Guguloth; Nitin A Randive; Bharat U Shinde; Anamika Thakur; Dhananjay I Patel; Mohd Raja; Michael J Green; Jennifer Alfaro; Patricio Avila; Felipe Pérez de Arce; Ramona G Almirez; Stacy Kanno; Sebastián Bernales; David T Hung; Sarvajit Chakravarty; Emma McCullagh; Kevin P Quinn; Roopa Rai; Son M Pham
Journal:  ACS Med Chem Lett       Date:  2016-10-28       Impact factor: 4.345

7.  αC helix as a switch in the conformational transition of Src/CDK-like kinase domains.

Authors:  He Huang; Ruijun Zhao; Bradley M Dickson; Robert D Skeel; Carol Beth Post
Journal:  J Phys Chem B       Date:  2012-04-05       Impact factor: 2.991

8.  Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study.

Authors:  Sarangan Ravichandran; Brian T Luke; Jack R Collins
Journal:  J Mol Graph Model       Date:  2015-01-12       Impact factor: 2.518

9.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Authors:  Sabine Ponader; Jan A Burger
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

Review 10.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.